Feature

What MSM Might Help—and Where the Evidence Falls Short

By Carla Voss · 2026-08-10

The short answer: which MSM benefits are credible?

The most credible potential benefit of MSM—methylsulfonylmethane—is modest, short-term relief of selected symptoms in people with knee osteoarthritis or mild knee pain. A few randomized trials have reported improvements in pain, swelling, physical-function scores, daily activities, or quality-of-life measures after roughly 12 weeks. That is a signal worth taking seriously, but it is not proof that MSM is an effective arthritis treatment.

The qualifications matter. Most studies have been small and brief, doses have varied, and positive results have not appeared consistently across all outcomes. Pain may improve while stiffness does not. A questionnaire score may change while walking and stair climbing remain no easier. The overall evidence is therefore less convincing than supplement advertising often suggests.

A useful way to rank the claimed benefits is:

Modest but uncertain evidence: selected pain, swelling, or function outcomes in knee osteoarthritis and mild knee pain.
Preliminary or mixed evidence: exercise-related soreness and muscle damage, allergic-rhinitis symptoms, and measured or photographed signs of skin aging.
Little or no reliable human evidence: hair growth, stronger nails, immune enhancement, digestive health, wound healing, energy, metabolism, circulation, cancer, rheumatoid arthritis, tendon disorders, interstitial cystitis, and broad claims about inflammation.

Even the first tier concerns symptom management, not repair of the underlying joint disease. MSM has not been shown to restore lost cartilage, reverse osteoarthritis, prevent structural deterioration, or otherwise modify disease progression. A person could experience less pain without any change in the condition causing that pain.

The defensible conclusion is therefore neither “MSM works” nor “MSM does nothing.” It is narrower: MSM may provide a small short-term improvement in selected knee symptoms for some people, but the size, consistency, and clinical importance of that benefit remain uncertain.

What MSM is—and what it is not

MSM stands for methylsulfonylmethane, an organosulfur compound also called dimethyl sulfone. It occurs naturally in small quantities in foods that may include fruits, vegetables, grains, milk, meat, seafood, coffee, and tea.

Its natural presence in food can be misleading when used in supplement marketing. Ordinary dietary exposure is far below the gram-level quantities commonly used in clinical trials. Eating foods that contain trace amounts of MSM is not equivalent to taking several grams of purified MSM, and natural occurrence does not by itself establish the effectiveness or safety of high-dose supplementation.

Commercial MSM does not necessarily come from extracting large quantities of food. It can be manufactured by oxidizing dimethyl sulfoxide, or DMSO, and then purified through crystallization or distillation. A peer-reviewed review describes the food sources, manufacturing process, and uncertainty surrounding effective doses and treatment durations in its overview of MSM applications and safety.

MSM and DMSO are chemically related, but they are not interchangeable. They have different properties, uses, routes of administration, and safety considerations. This distinction is especially important when interpreting reviews that pool trials of the two substances. If an analysis combines one MSM study with several DMSO studies, its pooled result cannot tell readers how well MSM itself works.

MSM is also not validated as a treatment merely because it contains sulfur. Proposed biological roles—such as effects on oxidative stress, inflammatory signaling, or connective-tissue chemistry—may help researchers form hypotheses. They do not demonstrate that an MSM supplement produces a noticeable health improvement in people.

The same principle applies to regulatory status. One branded MSM ingredient was reported to have received Generally Recognized as Safe, or GRAS, status for specified uses. That product-specific determination does not show that MSM treats arthritis or another disease. It also does not establish that every retail MSM product has identical purity, dose accuracy, manufacturing quality, or safety.

In short:

“Found in food” does not mean gram-level supplements behave like food.
“Contains sulfur” does not establish a therapeutic effect.
“Chemically related to DMSO” does not turn DMSO evidence into MSM evidence.
“GRAS” does not mean proven to work, risk-free for everyone, or suitable for indefinite use.

What the knee studies actually found

The knee research is the central reason MSM remains scientifically plausible rather than entirely evidence-free. Looking trial by trial, however, shows why the conclusion remains cautious.

Study population	MSM protocol	Duration	Main reported findings	Major limitations and source
50 adults aged 40–76 with knee osteoarthritis pain	3 g twice daily, or 6 g daily	12 weeks	Better WOMAC pain and physical-function impairment scores and an SF-36 daily-activities measure than placebo	Small pilot; no notable improvement in WOMAC stiffness or the aggregated total-symptom score; short follow-up; sponsor supplied grant support and products in the published trial
118 people with knee osteoarthritis	500 mg three times daily, or 1.5 g daily	12 weeks	Improvements in pain and swelling; the MSM-plus-glucosamine group had the largest reported improvements	The combination result cannot be attributed to MSM alone in Arthritis UK’s trial assessment
60 people in a knee trial	3.375 g daily	12 weeks	Reported improvement in pain and general functional well-being	No improvement in walking or stair climbing; available only as a conference summary in the same Arthritis UK assessment
88 otherwise healthy Japanese adults with mild knee pain	2 g daily	12 weeks	Statistically significant improvement in a knee questionnaire	Not a diagnosed-osteoarthritis population; small trial; primary result had a p-value of 0.046; three of four authors had company research-and-development affiliations in the 2023 trial report

The 50-person pilot provides some of the clearest MSM-only evidence. Participants with knee osteoarthritis pain were randomized to MSM or placebo. MSM produced better results on selected pain, physical-function, and daily-activity measures, but not on stiffness or the combined total-symptom score. No major adverse events emerged during the intervention, although a trial of this size and duration cannot establish long-term effectiveness or safety.

That pattern—positive findings for some measures but not others—is more informative than a blanket statement that MSM “improved arthritis.” A participant might report somewhat less pain while finding stairs equally difficult and remaining just as stiff in the morning. The intervention may have had an effect, but its practical value would be more limited than a broad improvement in joint function.

The 118-person trial used a lower daily dose and reported improvements in pain and swelling. The group receiving MSM plus glucosamine showed the largest changes, but that does not prove that MSM becomes more effective when paired with glucosamine. The result could reflect glucosamine, MSM, an interaction between them, chance, or a mixture of those factors. A multi-ingredient intervention cannot isolate the contribution of one ingredient unless the study is designed to do so.

The 60-person trial reportedly found better pain and general functional well-being, yet walking and stair climbing did not improve. Its availability only as a conference summary in the cited assessment also prevented a full evaluation of its methods and results. That makes it less dependable than a complete peer-reviewed report.

The newer trial requires a separate label because it did not enroll patients with established osteoarthritis. It studied otherwise healthy Japanese adults with mild knee pain. The primary questionnaire result favored MSM, but the p-value was close to the conventional 0.05 threshold. The information available here does not provide enough context about the between-group effect size and its uncertainty to judge confidently whether the average difference was noticeable or important to participants.

A p-value below 0.05 is commonly called statistically significant, but statistical significance does not answer the practical question. A small questionnaire difference can cross a statistical threshold without producing a meaningful improvement in walking, sleep, work, or other daily activities. Clinical interpretation requires the size of the effect, the uncertainty around it, and evidence that the change matters to patients.

These studies should not be stretched beyond what they tested. Evidence concerning knees does not establish that MSM relieves pain in the back, shoulders, hands, hips, or every other joint. Results in osteoarthritis do not demonstrate effectiveness for rheumatoid arthritis, tendonitis, sports injuries, or broad inflammatory disorders. Results in otherwise healthy adults with mild knee discomfort are also not equivalent to results in patients with diagnosed osteoarthritis.

Why positive trials still add up to an uncertain conclusion

Individual trial summaries often emphasize the outcomes that improved. Systematic reviews ask a harder question: when all eligible evidence is considered together, how confident can we be that the effect is real, repeatable, and clinically worthwhile?

MSM research has several recurring weaknesses:

Small participant groups
Treatment periods usually around 12 weeks
Different doses and formulations
Different symptom scales and endpoints
Positive findings for selected outcomes but not others
Little independent replication
Limited evidence about what happens after treatment stops
Occasional manufacturer support or company-affiliated researchers

A 2008 systematic review found that both included MSM randomized trials reported positive pain outcomes. But the MSM evidence consisted of only two trials, covering 168 patients in total and just 52 receiving active MSM. The reviewers concluded that definitive efficacy, optimal dosing, treatment duration, and longer-term safety had not been established in their systematic review of MSM and DMSO.

A later meta-analysis included three trials with 326 participants, but two evaluated DMSO and only one evaluated MSM. Under the authors’ random-effects analysis, the pooled pain reduction was not statistically and clinically significant. The estimated difference was 6.34 mm on a visual-analogue pain scale, with a 95% confidence interval ranging from −0.49 to 13.17 mm, and the study results varied significantly according to the 2011 meta-analysis.

That result does not prove that MSM is ineffective. It shows that the pooled evidence did not establish a dependable, meaningful effect. Because most of the included trials concerned DMSO, the analysis also cannot settle MSM-specific effectiveness. Combining chemically related substances may increase the amount of data in a calculation, but it does not erase the fact that they are distinct interventions.

Clinical importance is a separate issue from statistical detection. A result can be statistically detectable because the data are sufficiently consistent yet still be too small to matter to patients. Conversely, a potentially useful difference may fail to reach statistical significance when a study is too small. Readers therefore need more than the words “significant” or “not significant.”

The dates of the reviews also matter. The 2008 review searched literature through November 2007, while the literature search underlying the later meta-analysis ended in 2008. Those reviews could not include research published afterward, such as the 2023 mild-knee-pain trial. But adding another small, 12-week study does not automatically correct the older evidence base’s central weaknesses. What remains missing is a body of adequately powered, independently replicated MSM-only trials with clinically meaningful outcomes and longer follow-up.

Funding and affiliations deserve context rather than reflexive dismissal. The 50-person pilot received sponsor grant support and study products, although its authors reported no employment or direct financial relationship with the sponsor. The 2023 trial had three authors affiliated with a company research-and-development department. Neither fact proves that a result is wrong. Both increase the value of transparent reporting and independent replication when the total evidence base is already small.

The appropriate summary is therefore possible modest short-term benefit, not proven arthritis treatment.

Exercise recovery, allergies, and skin: promising signals or marketing?

Beyond knee symptoms, MSM research consists largely of early signals. These findings can justify better trials, but they are not strong enough to support confident consumer promises.

Exercise recovery: limited and mixed. Small studies have tested protocols around 3 g daily, 50 mg per kilogram of body weight, or similar short-term approaches. Some have reported less soreness or joint pain, altered inflammatory signaling, greater antioxidant activity, or lower biochemical indications of exercise-related muscle damage.

Those outcomes are not interchangeable. A change in a blood marker does not necessarily mean that an athlete feels better, recovers faster, performs better, or avoids injury. Slightly less soreness after one exercise challenge does not demonstrate reliable recovery benefits across different sports, training schedules, or levels of fitness.

The findings also conflict. One 18-person study reported improved biochemical markers after exercise, whereas a trial involving 24 runners found no significant differences in muscle pain, oxidative damage, or muscle-damage outcomes. A medically reviewed monograph characterizes the exercise evidence as inconsistent and based on small studies in its MSM clinical summary.

Different exercise protocols add further uncertainty. A supplement might be taken for several days before a run, for weeks before a half marathon, or around an exhaustive laboratory test. Participants may be trained runners, recreationally active adults, or people unaccustomed to the exercise. These designs do not answer precisely the same question.

The current evidence does not establish that MSM reliably speeds recovery, prevents muscle damage, improves athletic performance, or reduces injury risk.

Allergic rhinitis: preliminary. Examine’s evidence table characterizes the result as a small improvement based on one study involving 55 participants in its assessment of MSM.

A separate consumer medical reference describes a protocol of 2,600 mg daily for 30 days that reportedly improved upper- and lower-respiratory symptoms and energy in its overview of MSM research.

One small evidence base with uncertain replication is not enough to establish MSM as an allergy treatment. A change in a symptom questionnaire also does not show that MSM treats the biological cause of an individual’s allergies or can replace established care. Breathing difficulty and persistent respiratory symptoms should not be managed through supplement experimentation alone.

Skin aging: preliminary. A small 16-week study using 3 g daily reportedly found photographic improvements in crow’s feet and overall facial wrinkling. That is an interesting cosmetic signal, but one small study cannot establish a general anti-aging benefit. Photographic ratings, wrinkle measurements, skin elasticity, and clinically important changes in skin health are different endpoints.

Topical claims require additional caution. A study involving 46 participants reported improvement in rosacea with a product containing both MSM and silymarin as summarized by EBSCO’s clinical reference. Because both ingredients were used together, the result cannot be attributed to MSM. It also cannot be assumed that oral and topical MSM have equivalent absorption, effects, or risks.

Across these categories, the distinction is straightforward:

Biomarker change: potentially useful for understanding a mechanism.
Questionnaire change: may reflect a symptom difference but requires context about size and importance.
Photographic or measured skin change: may support a cosmetic hypothesis.
Established clinical benefit: requires consistent, replicated evidence showing meaningful outcomes.

Exercise recovery, allergy, and skin findings have not reached that final category.

Popular MSM claims that outrun the evidence

MSM has been promoted for far more conditions than human trials can support. Historical patents and commercial materials have associated it with increased energy, faster metabolism, enhanced circulation, wound healing, softer skin, stronger nails, pain relief, and other broad effects. A modern clinical monograph notes that many such historical claims have little supporting scientific evidence.

Claims requiring particular skepticism include:

Hair growth or reduced hair loss
Stronger or faster-growing nails
Enhanced immunity
Better digestion or relief of constipation
Faster wound healing
Greater energy or metabolism
Improved circulation
Cancer prevention or treatment
Interstitial-cystitis relief
Rheumatoid-arthritis treatment
Tendonitis relief
Broad, whole-body anti-inflammatory effects

For interstitial cystitis, the support described in the available evidence consists of case reports, anecdotes, or other small-scale reports rather than controlled clinical trials. That kind of evidence can identify a question worth investigating, but it cannot determine whether MSM works better than placebo, usual care, or the natural fluctuation of symptoms.

Mechanistic evidence is also frequently overinterpreted. MSM has been studied in cells and animals for possible effects on cytokines, oxidative stress, glutathione, and inflammatory pathways. These experiments may reveal biochemical activity. They do not show that an oral supplement produces a meaningful benefit in a person, at a tolerable dose, for a particular condition.

The gap from mechanism to treatment is substantial. A compound can alter a laboratory pathway without being absorbed adequately, reaching the relevant tissue, producing a useful effect, or improving how a patient feels or functions. An effect in mice does not establish the same effect in humans. A reduction in one cytokine does not prove that a supplement treats an inflammatory disease.

It is therefore inappropriate to call MSM a potent anti-inflammatory in humans based solely on laboratory or animal results. The human evidence is condition-specific and much narrower: small trials have examined selected symptoms, mainly involving knees.

Combination products create another common source of overclaiming. A study of MSM with glucosamine, chondroitin, silymarin, or several other ingredients tests the whole formulation. Even when participants improve, the study cannot show that MSM caused the result unless its design isolates MSM’s contribution.

A concise evidence map looks like this:

Insufficient human evidence: hair, nails, immunity, digestion, wound healing, energy, metabolism, circulation, cancer, rheumatoid arthritis, tendonitis, and interstitial cystitis.
Combination-only evidence: some joint, lower-back-pain, and rosacea formulations. These do not establish MSM-specific effects.
Animal or laboratory evidence: anti-inflammatory pathways, cytokines, oxidative stress, glutathione, and various disease models. These generate hypotheses rather than prove benefits.
Unsupported or weakly supported marketing claims: detoxification, cartilage rebuilding, disease reversal, universal pain relief, and broad immune enhancement.

The absence of strong evidence is not proof that every claim is impossible. It means consumers cannot currently rely on those claims when deciding whether MSM is likely to help.

Doses and timelines used in research

The following numbers describe research protocols, not personalized dosing recommendations.

Knee studies have commonly tested approximately 1.5 to 6 g of oral MSM daily, often divided into two or three doses, for up to 12 weeks. Examples include:

1.5 g daily: 500 mg three times daily in the 118-person osteoarthritis trial
2 g daily: the 2023 trial in adults with mild knee pain
3.375 g daily: the 60-person knee trial
6 g daily: 3 g twice daily in the 50-person osteoarthritis pilot

Across a broader range of human research, studied oral doses have ranged from approximately 500 mg to 6 g daily, with treatment periods from 10 days to 16 weeks, according to Examine’s evidence summary covering MSM dosing and trial duration.

This variation does not reveal one optimal dose. Different studies examined different populations, conditions, formulations, outcomes, and schedules. There has not been a definitive dose-ranging program showing that one amount offers the best balance of benefit and risk.

Higher doses should not be assumed to work better. A dose at the top of a research range may add cost or adverse effects without adding benefit. Nor does tolerating a dose for 12 or 16 weeks establish that the same amount is safe for a year or for indefinite use.

The trials also do not establish a universal time-to-benefit. Several knee studies assessed outcomes at 12 weeks, but that does not prove benefits began only at that point or that everyone who might respond must do so within the same period. It also does not provide a validated stopping rule.

Short exercise studies and longer cosmetic studies address different outcomes and cannot be used to predict when knee symptoms might improve. Study duration is an observation about the protocol, not an instruction to continue until that date regardless of benefit or adverse effects.

Food is not a practical substitute for the protocols used in these trials. Foods containing MSM provide amounts far below supplemental gram-level doses. Conversely, the presence of trace MSM in food does not establish that several grams of isolated MSM have the same safety profile as normal dietary exposure.

Anyone considering MSM should separate three questions:

What amount did a specific study test?
Was that study population and outcome relevant to the person’s situation?
Is that protocol appropriate and safe for the individual?

Research can answer the first question. It only partly answers the second and cannot answer the third without individual medical context.

Safety, side effects, and deciding whether to try MSM

Short-term oral MSM has generally been well tolerated in small clinical trials. Gastrointestinal complaints are among the most frequently reported adverse effects, and serious events have not been prominent in the brief knee studies. That record is somewhat reassuring, but it is not comprehensive.

Reported or suspected effects include:

Gastrointestinal discomfort
Bloating
Nausea
Diarrhea
Constipation
Indigestion
Headache
Fatigue
Insomnia
Concentration problems
Allergic reactions
Rash

This list does not mean every symptom is common or necessarily caused by MSM. The summarized clinical studies generally lasted no longer than 16 weeks, and small trials are poorly suited to detecting rare events, effects in medically complex people, or problems that emerge only after prolonged exposure. Long-term effectiveness and safety therefore remain unknown, as the adverse-effect and safety limitations in the Drugs.com clinical monograph make clear.

Interactions are another area where wording matters. Some references report no well-documented or clinically significant interactions. That does not prove interactions are impossible. Research has been limited, and uncommon interactions may not appear in small studies involving carefully selected participants.

People taking prescription medicines, over-the-counter pain relievers, or multiple supplements should ask a clinician or pharmacist to evaluate their specific combination. A generic interaction checker cannot account for every ingredient, dose, medical condition, or area of uncertainty.

Safety evidence is limited or missing for:

Pregnancy
Breastfeeding
Children
People with liver disease
People with kidney disease

Maximum safe doses have not been established for these groups, according to the limitations summarized in EBSCO’s clinical reference. The absence of a known contraindication should not be interpreted as positive evidence of safety.

Oral and topical MSM must also be treated as separate interventions. A capsule trial cannot establish the safety or effectiveness of a cream, and a topical combination study cannot validate oral supplementation. Examine’s safety review reports that one randomized trial found increased lower-extremity swelling with topical MSM in participants with venous insufficiency. People with that condition should not assume topical MSM is harmless merely because short oral trials were generally reassuring.

Before trying MSM for joint discomfort, a neutral decision framework can help:

Identify the actual problem. “Joint health” is too vague. Define the location, suspected cause, duration, and activities affected.
Choose one concrete outcome. Examples include pain during a specific walk, morning-stiffness duration, stair-climbing ability, or interference with sleep.
Do not confuse a combination product with an MSM test. If the supplement contains glucosamine, chondroitin, herbs, or analgesic ingredients, any change cannot confidently be attributed to MSM.
Keep other variables reasonably stable. Simultaneously changing exercise, medication, diet, footwear, and several supplements makes the result difficult to interpret.
Watch for adverse effects. Stop self-experimentation and seek professional advice if symptoms worsen or concerning effects appear.
Do not let supplementation delay diagnosis. As a precaution, persistent, severe, traumatic, acutely swollen, hot, unstable, or unexplained joint symptoms should receive medical evaluation rather than supplement-only management.

Frequently asked questions

Does MSM actually help knee osteoarthritis pain?

Possibly, but the benefit is not firmly established. Small randomized trials have found improvements in selected pain and physical-function measures. Other outcomes—including stiffness, total symptoms, walking, and stair climbing—have not improved consistently.

The 2008 systematic review discussed above found positive but inconclusive MSM evidence, while the later pooled DMSO/MSM analysis did not establish a clinically meaningful overall effect. The fairest summary is that MSM may offer modest short-term symptom relief for some people with knee osteoarthritis, while the average size and practical importance of the benefit remain uncertain.

MSM has not been shown to rebuild cartilage, reverse osteoarthritis, or alter disease progression.

How long does MSM take to work?

There is no validated universal time-to-benefit. Several knee trials assessed outcomes after 12 weeks, while research in other areas has used periods ranging from days to 16 weeks. Those assessment points do not prove exactly when a benefit began or how long an individual should continue.

If MSM is being considered with professional guidance, it is more useful to define a specific symptom or activity to monitor than to wait indefinitely for a general sense of improvement. The available evidence does not establish an evidence-based stopping rule or support indefinite use.

Can MSM help muscle soreness after exercise?

It might reduce soreness or selected biochemical markers under some conditions, but the evidence is limited and mixed. Very small studies have sometimes reported less soreness, joint pain, inflammatory signaling, or biochemical evidence of muscle damage. Other research found no significant differences in muscle pain, oxidative damage, or muscle-damage outcomes.

The studies used different exercise challenges, protocols, and participant groups. They do not demonstrate that MSM reliably speeds recovery, prevents muscle damage, improves performance, or reduces injury risk.

What side effects and interaction uncertainties does MSM have?

Reported effects include gastrointestinal discomfort, bloating, nausea, diarrhea, constipation, indigestion, headache, fatigue, insomnia, concentration problems, allergic reactions, and rash. Most reported effects in short trials were mild, but those trials were not large or long enough to rule out uncommon or delayed problems.

Few interactions have been documented, yet interaction research remains limited. People taking medicines or multiple supplements should ask a clinician or pharmacist about their specific situation. Safety is particularly uncertain during pregnancy and breastfeeding, in children, and for people with liver or kidney disease.

Are MSM and DMSO the same thing?

No. MSM, or methylsulfonylmethane, is also called dimethyl sulfone. DMSO is dimethyl sulfoxide. The two compounds are chemically related but distinct, with different properties, uses, routes of administration, and safety considerations.

This distinction affects evidence interpretation. A review that pools DMSO and MSM trials cannot establish an MSM-specific benefit, particularly when only one included trial actually tested MSM. Evidence for DMSO should not be presented as though it directly proves that MSM works.

MSM is neither a proven arthritis treatment nor an evidence-free supplement. Small human trials support the possibility of modest short-term improvement in selected knee-pain or function measures, but inconsistent outcomes and inconclusive reviews keep confidence limited. Exercise, allergy, and skin claims remain preliminary, while most broader marketing claims lack reliable human support.

Study doses should be treated as research context, not instructions. An optimal dose, long-term safety, long-term effectiveness, and clinically important interactions have not been established. Persistent or concerning symptoms deserve professional evaluation rather than indefinite supplement experimentation.

Bulk MSM describes itself as an educational site, not a medical provider. This article provides general information and is not medical advice; the publisher’s terms likewise recommend speaking with a doctor before starting a supplement. Consult a qualified healthcare professional for guidance based on your symptoms, medical conditions, medicines, and other supplements.